| Literature DB >> 23942113 |
Takuya Yamane1, Sato Murao, Izumi Kato-Ose, Lisa Kashima, Motoki Yuguchi, Miyuki Kozuka, Keisuke Takeuchi, Hisakazu Ogita, Iwao Ohkubo, Hiroyoshi Ariga.
Abstract
Legumain (EC 3.4.22.34) is an asparaginyl endopeptidase. Strong legumain activity was observed in the mouse kidney, and legumain was found to be highly expressed in tumors. We previously reported that bovine kidney annexin A2 was co-purified with legumain and that legumain cleaved the N-terminal region of annexin A2 at an Asn residue in vitro and in vivo. In this study, we found a p53-binding site in intron 1 of the human legumain gene using computational analysis. To determine whether transcription of the legumain gene is regulated by p53, HCT116 cells were transfected with p53 siRNA and the effect of knockdown of p53 expression on legumain expression was examined. The results showed that expression levels of both legumain mRNA and protein were decreased in the siRNA-treated cells. Furthermore, enzyme activity of legumain was also increased by doxorubicin and its activity was reduced by knockdown of p53 in HCT116 cells. These results suggest that legumain expression and its enzyme activity are regulated by p53.Entities:
Keywords: DXR; Doxorubicin; Legumain; MCA; Z; benzyloxycarbonyl; doxorubicin; methylcumarinamide; p53
Mesh:
Substances:
Year: 2013 PMID: 23942113 DOI: 10.1016/j.bbrc.2013.08.007
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575